| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cystic Fibrosis | 35 | 2026 | 267 | 8.600 |
Why?
|
| Liver Transplantation | 28 | 2026 | 1136 | 4.560 |
Why?
|
| Liver Diseases | 18 | 2026 | 378 | 4.110 |
Why?
|
| Hypertension, Portal | 8 | 2022 | 78 | 2.880 |
Why?
|
| Liver Cirrhosis | 19 | 2025 | 901 | 2.510 |
Why?
|
| Hepatitis C, Chronic | 9 | 2025 | 356 | 2.470 |
Why?
|
| Elasticity Imaging Techniques | 7 | 2024 | 157 | 2.270 |
Why?
|
| Antiviral Agents | 10 | 2025 | 802 | 1.880 |
Why?
|
| Hepatitis B | 4 | 2016 | 170 | 1.590 |
Why?
|
| Alagille Syndrome | 3 | 2022 | 54 | 1.570 |
Why?
|
| Liver | 18 | 2026 | 1783 | 1.550 |
Why?
|
| Cholestasis | 4 | 2022 | 170 | 1.510 |
Why?
|
| Immunosuppressive Agents | 6 | 2026 | 656 | 1.470 |
Why?
|
| Hepatitis B Vaccines | 3 | 2016 | 49 | 1.350 |
Why?
|
| Child | 65 | 2026 | 26166 | 1.230 |
Why?
|
| Hepatitis B virus | 3 | 2015 | 132 | 1.210 |
Why?
|
| Sirolimus | 2 | 2025 | 231 | 1.150 |
Why?
|
| Esophageal and Gastric Varices | 4 | 2022 | 72 | 1.110 |
Why?
|
| End Stage Liver Disease | 4 | 2025 | 193 | 1.100 |
Why?
|
| Sofosbuvir | 2 | 2025 | 20 | 1.100 |
Why?
|
| Gastroenterology | 4 | 2024 | 224 | 1.040 |
Why?
|
| Child, Preschool | 38 | 2026 | 15001 | 1.000 |
Why?
|
| Aspartate Aminotransferases | 5 | 2024 | 80 | 0.980 |
Why?
|
| Graft Rejection | 3 | 2025 | 556 | 0.970 |
Why?
|
| Liver Failure, Acute | 2 | 2026 | 95 | 0.910 |
Why?
|
| Adenovirus Infections, Human | 2 | 2023 | 61 | 0.910 |
Why?
|
| Hepatitis C | 3 | 2020 | 376 | 0.880 |
Why?
|
| Cyclopropanes | 2 | 2025 | 67 | 0.840 |
Why?
|
| Ribavirin | 2 | 2025 | 85 | 0.830 |
Why?
|
| Carbamates | 2 | 2024 | 63 | 0.830 |
Why?
|
| Hepacivirus | 6 | 2024 | 271 | 0.810 |
Why?
|
| Transplant Recipients | 3 | 2021 | 230 | 0.810 |
Why?
|
| Humans | 91 | 2026 | 130074 | 0.760 |
Why?
|
| Portal Vein | 3 | 2022 | 84 | 0.710 |
Why?
|
| Perioperative Care | 3 | 2021 | 217 | 0.700 |
Why?
|
| Severity of Illness Index | 13 | 2024 | 3026 | 0.700 |
Why?
|
| Aminophenols | 3 | 2026 | 14 | 0.700 |
Why?
|
| Benzodioxoles | 3 | 2026 | 17 | 0.690 |
Why?
|
| Pyrrolidines | 4 | 2026 | 50 | 0.690 |
Why?
|
| Sulfonamides | 2 | 2021 | 298 | 0.680 |
Why?
|
| Cholestasis, Intrahepatic | 1 | 2022 | 59 | 0.680 |
Why?
|
| Biliary Atresia | 3 | 2022 | 224 | 0.670 |
Why?
|
| Infant | 30 | 2026 | 13266 | 0.650 |
Why?
|
| Liver Neoplasms | 6 | 2025 | 1366 | 0.640 |
Why?
|
| Cytochrome P-450 CYP3A Inhibitors | 1 | 2020 | 10 | 0.640 |
Why?
|
| Uracil | 1 | 2020 | 12 | 0.640 |
Why?
|
| Gastroenteritis | 1 | 2023 | 306 | 0.640 |
Why?
|
| Lactams, Macrocyclic | 1 | 2020 | 33 | 0.640 |
Why?
|
| Adolescent | 32 | 2026 | 20794 | 0.630 |
Why?
|
| Indoles | 3 | 2026 | 200 | 0.630 |
Why?
|
| Anilides | 1 | 2020 | 52 | 0.630 |
Why?
|
| Ritonavir | 1 | 2020 | 45 | 0.620 |
Why?
|
| Proline | 1 | 2020 | 79 | 0.620 |
Why?
|
| Hepatoblastoma | 4 | 2023 | 204 | 0.580 |
Why?
|
| Lung Transplantation | 3 | 2024 | 356 | 0.580 |
Why?
|
| Viral Hepatitis Vaccines | 1 | 2018 | 19 | 0.560 |
Why?
|
| Pyrazoles | 3 | 2026 | 355 | 0.560 |
Why?
|
| Fatty Liver | 3 | 2025 | 220 | 0.560 |
Why?
|
| Male | 47 | 2026 | 64380 | 0.550 |
Why?
|
| Neonatal Screening | 4 | 2021 | 204 | 0.540 |
Why?
|
| Hepatitis B Surface Antigens | 3 | 2015 | 60 | 0.540 |
Why?
|
| Waiting Lists | 2 | 2016 | 251 | 0.520 |
Why?
|
| Quinolones | 3 | 2026 | 58 | 0.510 |
Why?
|
| Hepatitis B, Chronic | 1 | 2018 | 84 | 0.510 |
Why?
|
| Female | 45 | 2026 | 70239 | 0.510 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2018 | 224 | 0.510 |
Why?
|
| Postoperative Complications | 6 | 2026 | 3114 | 0.500 |
Why?
|
| Pediatrics | 6 | 2024 | 1242 | 0.490 |
Why?
|
| Biomarkers | 9 | 2026 | 3358 | 0.480 |
Why?
|
| Pancreatic Cyst | 1 | 2016 | 28 | 0.480 |
Why?
|
| Platelet Count | 7 | 2024 | 139 | 0.470 |
Why?
|
| Registries | 7 | 2026 | 1607 | 0.460 |
Why?
|
| Weight Gain | 1 | 2017 | 385 | 0.430 |
Why?
|
| Chemical and Drug Induced Liver Injury | 2 | 2015 | 149 | 0.420 |
Why?
|
| Biopsy | 5 | 2025 | 1240 | 0.420 |
Why?
|
| Gastrointestinal Hemorrhage | 4 | 2022 | 229 | 0.410 |
Why?
|
| Drug Therapy, Combination | 4 | 2025 | 1165 | 0.410 |
Why?
|
| Hepatitis B Antibodies | 1 | 2013 | 24 | 0.410 |
Why?
|
| Hemangiosarcoma | 1 | 2014 | 47 | 0.400 |
Why?
|
| Drug Combinations | 5 | 2026 | 266 | 0.400 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2014 | 122 | 0.390 |
Why?
|
| Treatment Outcome | 18 | 2026 | 12818 | 0.390 |
Why?
|
| Hematologic Diseases | 1 | 2013 | 82 | 0.380 |
Why?
|
| Retrospective Studies | 20 | 2026 | 17537 | 0.370 |
Why?
|
| Adenoviruses, Human | 2 | 2023 | 97 | 0.370 |
Why?
|
| Urea Cycle Disorders, Inborn | 2 | 2025 | 83 | 0.370 |
Why?
|
| Risk Factors | 11 | 2025 | 10959 | 0.360 |
Why?
|
| Exocrine Pancreatic Insufficiency | 2 | 2025 | 38 | 0.350 |
Why?
|
| Body Height | 3 | 2017 | 192 | 0.320 |
Why?
|
| Graft Survival | 3 | 2025 | 462 | 0.320 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2020 | 828 | 0.320 |
Why?
|
| Pyridines | 3 | 2026 | 258 | 0.310 |
Why?
|
| Gastrointestinal Diseases | 2 | 2025 | 336 | 0.310 |
Why?
|
| Dysbiosis | 2 | 2021 | 144 | 0.300 |
Why?
|
| Follow-Up Studies | 4 | 2022 | 5166 | 0.290 |
Why?
|
| Hepatomegaly | 1 | 2009 | 22 | 0.290 |
Why?
|
| Feces | 3 | 2022 | 718 | 0.290 |
Why?
|
| Prospective Studies | 12 | 2025 | 6401 | 0.280 |
Why?
|
| Failure to Thrive | 1 | 2009 | 87 | 0.280 |
Why?
|
| Infant, Newborn | 10 | 2025 | 8547 | 0.280 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 3 | 2024 | 400 | 0.270 |
Why?
|
| Alanine Transaminase | 1 | 2008 | 153 | 0.270 |
Why?
|
| Chloride Channel Agonists | 3 | 2025 | 8 | 0.260 |
Why?
|
| Mass Screening | 1 | 2013 | 817 | 0.260 |
Why?
|
| Body Weight | 3 | 2017 | 985 | 0.260 |
Why?
|
| Diarrhea | 1 | 2009 | 299 | 0.250 |
Why?
|
| Nutritional Status | 3 | 2019 | 297 | 0.240 |
Why?
|
| Time Factors | 4 | 2019 | 6165 | 0.240 |
Why?
|
| Perforin | 1 | 2026 | 24 | 0.240 |
Why?
|
| Fibrosis | 3 | 2023 | 420 | 0.240 |
Why?
|
| Growth Disorders | 2 | 2020 | 181 | 0.240 |
Why?
|
| Cohort Studies | 7 | 2024 | 5034 | 0.230 |
Why?
|
| Child Health | 1 | 2026 | 68 | 0.230 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2025 | 975 | 0.220 |
Why?
|
| Portasystemic Shunt, Surgical | 1 | 2024 | 8 | 0.220 |
Why?
|
| Paracentesis | 1 | 2024 | 20 | 0.210 |
Why?
|
| Disease Progression | 3 | 2020 | 2191 | 0.210 |
Why?
|
| Prevalence | 6 | 2026 | 2687 | 0.210 |
Why?
|
| United States | 7 | 2025 | 11894 | 0.210 |
Why?
|
| Young Adult | 7 | 2026 | 9978 | 0.210 |
Why?
|
| Genotype | 3 | 2024 | 2588 | 0.210 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 1 | 2024 | 31 | 0.210 |
Why?
|
| Benzimidazoles | 2 | 2024 | 155 | 0.210 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2024 | 50 | 0.200 |
Why?
|
| Gastrostomy | 1 | 2024 | 83 | 0.200 |
Why?
|
| Hospitals, Pediatric | 1 | 2009 | 800 | 0.200 |
Why?
|
| Interferon-gamma | 1 | 2026 | 542 | 0.200 |
Why?
|
| Embolization, Therapeutic | 1 | 2025 | 224 | 0.190 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2026 | 460 | 0.190 |
Why?
|
| Ultrasonography | 5 | 2021 | 942 | 0.190 |
Why?
|
| Matrix Metalloproteinase 7 | 1 | 2022 | 25 | 0.190 |
Why?
|
| Endoglin | 1 | 2022 | 30 | 0.190 |
Why?
|
| Terminology as Topic | 1 | 2024 | 226 | 0.190 |
Why?
|
| Frailty | 1 | 2025 | 140 | 0.190 |
Why?
|
| Age Factors | 3 | 2015 | 2822 | 0.180 |
Why?
|
| Wechsler Scales | 1 | 2022 | 18 | 0.180 |
Why?
|
| Enzyme Replacement Therapy | 2 | 2021 | 30 | 0.180 |
Why?
|
| Hepatitis | 1 | 2022 | 56 | 0.180 |
Why?
|
| Varicose Veins | 1 | 2022 | 27 | 0.180 |
Why?
|
| Interleukin-8 | 1 | 2022 | 200 | 0.180 |
Why?
|
| Severe Combined Immunodeficiency | 1 | 2022 | 107 | 0.170 |
Why?
|
| Patient Readmission | 1 | 2025 | 436 | 0.170 |
Why?
|
| Quinoxalines | 1 | 2021 | 39 | 0.170 |
Why?
|
| Prognosis | 4 | 2020 | 4848 | 0.170 |
Why?
|
| Argininosuccinate Lyase | 1 | 2021 | 61 | 0.160 |
Why?
|
| Fellowships and Scholarships | 1 | 2024 | 325 | 0.160 |
Why?
|
| 2-Naphthylamine | 1 | 2020 | 4 | 0.160 |
Why?
|
| Quinolines | 3 | 2026 | 115 | 0.160 |
Why?
|
| Metagenome | 1 | 2021 | 138 | 0.160 |
Why?
|
| Venous Thrombosis | 1 | 2022 | 164 | 0.160 |
Why?
|
| Logistic Models | 2 | 2015 | 1794 | 0.160 |
Why?
|
| Dimensional Measurement Accuracy | 1 | 2020 | 6 | 0.160 |
Why?
|
| Tablets | 1 | 2020 | 35 | 0.160 |
Why?
|
| Respiration, Artificial | 1 | 2023 | 500 | 0.160 |
Why?
|
| Cytomegalovirus | 1 | 2021 | 258 | 0.160 |
Why?
|
| Adenoviridae | 1 | 2023 | 581 | 0.160 |
Why?
|
| Multiple Organ Failure | 1 | 2021 | 145 | 0.160 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2022 | 211 | 0.160 |
Why?
|
| Anthropometry | 2 | 2018 | 187 | 0.160 |
Why?
|
| Practice Guidelines as Topic | 3 | 2024 | 1282 | 0.150 |
Why?
|
| Valine | 1 | 2020 | 110 | 0.150 |
Why?
|
| Breast Feeding | 2 | 2022 | 235 | 0.150 |
Why?
|
| Viral Nonstructural Proteins | 1 | 2020 | 136 | 0.150 |
Why?
|
| Ursodeoxycholic Acid | 2 | 2018 | 38 | 0.150 |
Why?
|
| Tracheostomy | 1 | 2021 | 210 | 0.140 |
Why?
|
| Metabolome | 1 | 2021 | 325 | 0.140 |
Why?
|
| Neoplasms | 1 | 2013 | 2977 | 0.140 |
Why?
|
| Immunocompromised Host | 1 | 2020 | 310 | 0.140 |
Why?
|
| Curriculum | 1 | 2024 | 792 | 0.140 |
Why?
|
| Cross-Sectional Studies | 3 | 2019 | 3782 | 0.140 |
Why?
|
| Protoporphyria, Erythropoietic | 1 | 2018 | 2 | 0.140 |
Why?
|
| Pseudomonas Infections | 2 | 2019 | 117 | 0.140 |
Why?
|
| Organ Transplantation | 1 | 2020 | 170 | 0.140 |
Why?
|
| Hyperplasia | 1 | 2018 | 189 | 0.140 |
Why?
|
| Age Distribution | 1 | 2019 | 421 | 0.140 |
Why?
|
| Microbiota | 1 | 2023 | 435 | 0.130 |
Why?
|
| Survival Analysis | 2 | 2021 | 1481 | 0.130 |
Why?
|
| Thrombosis | 1 | 2022 | 498 | 0.130 |
Why?
|
| Time-to-Treatment | 1 | 2019 | 208 | 0.130 |
Why?
|
| Growth | 1 | 2017 | 93 | 0.130 |
Why?
|
| Postoperative Care | 1 | 2019 | 294 | 0.130 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2021 | 468 | 0.120 |
Why?
|
| Obesity | 1 | 2008 | 2398 | 0.120 |
Why?
|
| Preoperative Care | 1 | 2019 | 357 | 0.120 |
Why?
|
| Nutritional Support | 1 | 2017 | 67 | 0.120 |
Why?
|
| Survival Rate | 2 | 2019 | 2107 | 0.120 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2017 | 75 | 0.120 |
Why?
|
| Proportional Hazards Models | 2 | 2018 | 1393 | 0.120 |
Why?
|
| Endovascular Procedures | 1 | 2024 | 778 | 0.120 |
Why?
|
| Infant Nutritional Physiological Phenomena | 1 | 2017 | 174 | 0.120 |
Why?
|
| Hepatitis D | 1 | 2015 | 3 | 0.120 |
Why?
|
| Critical Care | 1 | 2021 | 686 | 0.120 |
Why?
|
| Child Development | 2 | 2018 | 267 | 0.110 |
Why?
|
| Telecommunications | 1 | 2015 | 21 | 0.110 |
Why?
|
| Longitudinal Studies | 4 | 2021 | 1481 | 0.110 |
Why?
|
| Birth Weight | 1 | 2017 | 345 | 0.110 |
Why?
|
| Parenteral Nutrition | 1 | 2017 | 219 | 0.110 |
Why?
|
| Pancreas | 1 | 2016 | 218 | 0.110 |
Why?
|
| Referral and Consultation | 1 | 2019 | 551 | 0.110 |
Why?
|
| Patient Selection | 1 | 2019 | 723 | 0.110 |
Why?
|
| History, 20th Century | 1 | 2016 | 361 | 0.110 |
Why?
|
| Fluoroquinolones | 1 | 2015 | 94 | 0.110 |
Why?
|
| Creatinine | 1 | 2016 | 396 | 0.110 |
Why?
|
| Work | 1 | 2014 | 12 | 0.110 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2015 | 176 | 0.100 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2020 | 774 | 0.100 |
Why?
|
| Interferon-alpha | 1 | 2015 | 238 | 0.100 |
Why?
|
| Disease Management | 1 | 2017 | 554 | 0.100 |
Why?
|
| Mercaptopurine | 1 | 2013 | 72 | 0.100 |
Why?
|
| Antibodies | 1 | 2015 | 316 | 0.100 |
Why?
|
| Adult | 7 | 2025 | 31011 | 0.100 |
Why?
|
| Bilirubin | 2 | 2026 | 124 | 0.100 |
Why?
|
| Analysis of Variance | 1 | 2015 | 928 | 0.100 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2015 | 290 | 0.100 |
Why?
|
| Virus Activation | 1 | 2013 | 87 | 0.100 |
Why?
|
| Gestational Age | 1 | 2017 | 1210 | 0.100 |
Why?
|
| Allopurinol | 1 | 2013 | 79 | 0.100 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2014 | 387 | 0.090 |
Why?
|
| Enzyme Inhibitors | 1 | 2015 | 559 | 0.090 |
Why?
|
| DNA, Viral | 1 | 2013 | 451 | 0.090 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2014 | 259 | 0.090 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2013 | 194 | 0.090 |
Why?
|
| MicroRNAs | 1 | 2018 | 883 | 0.090 |
Why?
|
| Hepatectomy | 2 | 2023 | 130 | 0.080 |
Why?
|
| Faculty, Medical | 1 | 2014 | 281 | 0.080 |
Why?
|
| Risk Assessment | 2 | 2020 | 3677 | 0.080 |
Why?
|
| Family | 1 | 2014 | 587 | 0.080 |
Why?
|
| Hospital Mortality | 1 | 2015 | 1057 | 0.080 |
Why?
|
| Recurrence | 1 | 2014 | 1475 | 0.080 |
Why?
|
| Sensitivity and Specificity | 3 | 2024 | 2076 | 0.080 |
Why?
|
| Pruritus | 2 | 2022 | 51 | 0.080 |
Why?
|
| Quality of Life | 3 | 2025 | 2069 | 0.070 |
Why?
|
| Glycogen Storage Disease | 1 | 2009 | 8 | 0.070 |
Why?
|
| Philadelphia | 1 | 2009 | 29 | 0.070 |
Why?
|
| Body Mass Index | 1 | 2015 | 1694 | 0.070 |
Why?
|
| Diagnosis, Differential | 2 | 2018 | 1874 | 0.070 |
Why?
|
| Intubation, Gastrointestinal | 1 | 2009 | 52 | 0.070 |
Why?
|
| ROC Curve | 2 | 2021 | 609 | 0.070 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2015 | 744 | 0.070 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 2289 | 0.070 |
Why?
|
| Case-Control Studies | 3 | 2020 | 3349 | 0.070 |
Why?
|
| Hospitalization | 3 | 2021 | 1935 | 0.060 |
Why?
|
| Chronic Disease | 2 | 2024 | 1241 | 0.060 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2013 | 870 | 0.060 |
Why?
|
| Middle Aged | 3 | 2025 | 28314 | 0.060 |
Why?
|
| Neutropenia | 2 | 2020 | 209 | 0.060 |
Why?
|
| Yttrium Radioisotopes | 1 | 2025 | 22 | 0.060 |
Why?
|
| Societies, Medical | 2 | 2025 | 791 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2023 | 1265 | 0.060 |
Why?
|
| Argininosuccinic Aciduria | 1 | 2025 | 53 | 0.060 |
Why?
|
| Texas | 1 | 2013 | 3655 | 0.050 |
Why?
|
| Mycophenolic Acid | 1 | 2025 | 54 | 0.050 |
Why?
|
| Benzopyrans | 1 | 2024 | 19 | 0.050 |
Why?
|
| Sustained Virologic Response | 1 | 2024 | 46 | 0.050 |
Why?
|
| Lymphocyte Activation | 1 | 2026 | 630 | 0.050 |
Why?
|
| Margins of Excision | 1 | 2023 | 60 | 0.050 |
Why?
|
| Algeria | 1 | 2022 | 1 | 0.050 |
Why?
|
| Leukocyte L1 Antigen Complex | 1 | 2022 | 20 | 0.050 |
Why?
|
| Hepatic Artery | 1 | 2022 | 45 | 0.050 |
Why?
|
| gamma-Glutamyltransferase | 1 | 2021 | 49 | 0.040 |
Why?
|
| Catheters | 1 | 2022 | 79 | 0.040 |
Why?
|
| Viremia | 1 | 2022 | 130 | 0.040 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2023 | 376 | 0.040 |
Why?
|
| Ganciclovir | 1 | 2021 | 101 | 0.040 |
Why?
|
| Trachea | 1 | 2023 | 206 | 0.040 |
Why?
|
| Genotyping Techniques | 1 | 2021 | 110 | 0.040 |
Why?
|
| Fatigue | 1 | 2022 | 191 | 0.040 |
Why?
|
| Constipation | 1 | 2022 | 130 | 0.040 |
Why?
|
| Hyperammonemia | 1 | 2021 | 59 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 2 | 2023 | 2574 | 0.040 |
Why?
|
| Portoenterostomy, Hepatic | 1 | 2021 | 62 | 0.040 |
Why?
|
| Health Status | 1 | 2022 | 371 | 0.040 |
Why?
|
| Tacrolimus | 1 | 2020 | 100 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2023 | 820 | 0.040 |
Why?
|
| Prednisone | 1 | 2020 | 237 | 0.040 |
Why?
|
| Immunoglobulin M | 1 | 2020 | 207 | 0.040 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2021 | 208 | 0.040 |
Why?
|
| Body Size | 1 | 2020 | 62 | 0.040 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2021 | 125 | 0.040 |
Why?
|
| Education, Medical, Graduate | 1 | 2024 | 550 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2021 | 499 | 0.040 |
Why?
|
| Acute Disease | 1 | 2022 | 1153 | 0.040 |
Why?
|
| Tissue Donors | 1 | 2022 | 506 | 0.040 |
Why?
|
| Thrombocytopenia | 1 | 2020 | 220 | 0.040 |
Why?
|
| Histamine H2 Antagonists | 1 | 2019 | 47 | 0.040 |
Why?
|
| Respiratory Sounds | 1 | 2019 | 78 | 0.030 |
Why?
|
| Provitamins | 1 | 2018 | 3 | 0.030 |
Why?
|
| Cholestyramine Resin | 1 | 2018 | 13 | 0.030 |
Why?
|
| Photosensitivity Disorders | 1 | 2018 | 10 | 0.030 |
Why?
|
| Cholagogues and Choleretics | 1 | 2018 | 24 | 0.030 |
Why?
|
| Cough | 1 | 2019 | 97 | 0.030 |
Why?
|
| beta Carotene | 1 | 2018 | 35 | 0.030 |
Why?
|
| Allografts | 1 | 2019 | 220 | 0.030 |
Why?
|
| Gastrointestinal Tract | 1 | 2020 | 209 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 2020 | 781 | 0.030 |
Why?
|
| Metabolomics | 1 | 2021 | 500 | 0.030 |
Why?
|
| Anticoagulants | 1 | 2022 | 598 | 0.030 |
Why?
|
| Incidence | 1 | 2025 | 3321 | 0.030 |
Why?
|
| Critical Illness | 1 | 2021 | 623 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2024 | 1042 | 0.030 |
Why?
|
| Transplantation, Homologous | 1 | 2019 | 668 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2020 | 1374 | 0.030 |
Why?
|
| Diabetes Mellitus | 1 | 2024 | 888 | 0.030 |
Why?
|
| Proton Pump Inhibitors | 1 | 2019 | 275 | 0.030 |
Why?
|
| Uzbekistan | 1 | 2015 | 1 | 0.030 |
Why?
|
| Respiratory Tract Infections | 1 | 2019 | 295 | 0.030 |
Why?
|
| Hepatitis Delta Virus | 1 | 2015 | 5 | 0.030 |
Why?
|
| Ukraine | 1 | 2015 | 10 | 0.030 |
Why?
|
| Sclerotherapy | 1 | 2015 | 36 | 0.030 |
Why?
|
| Ligation | 1 | 2015 | 133 | 0.030 |
Why?
|
| Pandemics | 1 | 2022 | 1112 | 0.030 |
Why?
|
| Head | 1 | 2015 | 111 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 1604 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2015 | 183 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2020 | 1690 | 0.030 |
Why?
|
| Guanine Nucleotides | 1 | 2013 | 13 | 0.030 |
Why?
|
| Hypoxanthine Phosphoribosyltransferase | 1 | 2013 | 34 | 0.030 |
Why?
|
| Thionucleotides | 1 | 2013 | 21 | 0.030 |
Why?
|
| Biotransformation | 1 | 2013 | 54 | 0.030 |
Why?
|
| Drug Evaluation | 1 | 2013 | 101 | 0.030 |
Why?
|
| Primary Prevention | 1 | 2015 | 182 | 0.030 |
Why?
|
| Xanthine Oxidase | 1 | 2013 | 39 | 0.030 |
Why?
|
| Maintenance Chemotherapy | 1 | 2013 | 23 | 0.030 |
Why?
|
| Decision Making | 1 | 2019 | 712 | 0.030 |
Why?
|
| Hyperbilirubinemia | 1 | 2013 | 43 | 0.030 |
Why?
|
| Endoscopy | 1 | 2015 | 266 | 0.030 |
Why?
|
| Methyltransferases | 1 | 2013 | 78 | 0.020 |
Why?
|
| Inflammation | 1 | 2020 | 1478 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2022 | 4035 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2023 | 3739 | 0.020 |
Why?
|
| Methotrexate | 1 | 2013 | 348 | 0.020 |
Why?
|
| Lung | 1 | 2019 | 1531 | 0.020 |
Why?
|
| Vascular Surgical Procedures | 1 | 2015 | 535 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2014 | 1227 | 0.020 |
Why?
|
| Biomedical Research | 1 | 2015 | 558 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2013 | 1325 | 0.020 |
Why?
|
| Mutation | 1 | 2020 | 6067 | 0.010 |
Why?
|
| Aged | 1 | 2022 | 20821 | 0.010 |
Why?
|